| Name | Title | Contact Details |
|---|
VelosBio Inc. is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, ROR1-directed therapeutics to transform the lives of patients with cancer. Its lead candidate, VLS-101, is a ROR1-directed ADC being developed for patients with hematologic and solid tumor malignancies. The company is developing a broad pipeline of therapeutics targeting ROR1 in oncologic indications with high unmet medical need.
Octave is developing a comprehensive, first-in-class Care Management Platform.
Avitide is dedicated to advancing our partners’ clinical pipelines and commercial manufacturing processes with a rapid, exclusive, and enabling affinity purification platform technology.
KindredBio is focused on bringing groundbreaking products and innovative new technologies to veterinary medicine, because we believe our animal companions deserve the same kinds of safe and effective medicines that human family members enjoy.
AbSci is a global leader in biomanufacturing technologies. The company`s SoluPro™ expression platform achieves ultra-high yields of soluble and active protein products and enables ultra-high efficiency purification processes.